enVVeno Medical Provides Enrollment Update For Ongoing VenoValve U.S. Pivotal Study And Announces Upcoming Investor And KOL Events
Portfolio Pulse from Happy Mohamed
enVVeno Medical Corporation (NASDAQ:NVNO) has provided an update on its ongoing SAVVE U.S. pivotal study for the VenoValve, announcing that 57 patients have been enrolled so far, with full enrollment expected by the end of 2023. The company also announced two upcoming investor events. With $34.2 million in cash and investments, and a burn rate of between $4 million and $5 million per quarter, the company has sufficient resources to fund its current operations past the release of topline safety and efficacy data from the SAVVE study and through the end of 2024.
July 05, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
enVVeno Medical's ongoing SAVVE study for the VenoValve is progressing well with 57 patients enrolled so far and full enrollment expected by the end of 2023. The company's financial position is strong, with sufficient resources to fund its operations through 2024.
The news about the progress of the SAVVE study and the company's strong financial position is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100